| アブストラクト | BACKGROUND AND OBJECTIVE: A decrease in factor V activity has been reported in some patients treated with azathioprine or 6-mercaptopurine. This may lead to unnecessary treatment discontinuation in otherwise asymptomatic patients. Our aim was to review spontaneously reported cases of decreased factor V activity associated with both drugs and to identify the possible impact on patient care. METHODS: Cases of decrease in prothrombin (PT) or factor V activity involving purine analogs were extracted from the French pharmacovigilance database. Reports with evidence of disseminated intravascular coagulation, signs of acute hepatocellular failure, liver cirrhosis or concomitant vitamin K antagonist treatment were excluded. RESULTS: Twenty-four cases (azathioprine: 13 and 6-mercaptopurine: 11) were retained. Therapeutic indications were inflammatory bowel diseases in 11 patients, acute leukemia in eight, and other autoimmune diseases in five. PT activity before treatment was normal in all nine tested patients. The decrease in PT or factor V activity occurs after a median of 10 weeks of treatment and all patients were asymptomatic. The median PT and factor V activities values were 51.5% and 36.4%, respectively. Other coagulation factors were inconsistently decreased. Full recovery was observed within 3-60 days following purine analogs discontinuation. In four patients, drug rechallenge was associated with recurrence of the coagulation disorders. CONCLUSIONS: Although the mechanism remains unknown, this series that includes cases with positive drug reintroduction strongly suggests the causative role of these drugs. As all patients remained asymptomatic, treatment discontinuation should be carefully considered in patients who clearly benefits from this treatment. |
|---|
| ジャーナル名 | Clinics and research in hepatology and gastroenterology |
|---|
| Pubmed追加日 | 2014/6/24 |
|---|
| 投稿者 | Paret, Nathalie; Dautriche, Anne; Bera, Annie Pierre Jonville; Gouraud, Aurore; Millaret, Anne; Descotes, Jacques; Vial, Thierry |
|---|
| 組織名 | Centre regional de pharmacovigilance, 162, avenue Lacassagne, 69003 Lyon, France.;Centre regional de pharmacovigilance, hopital du Bocage, 10, boulevard;Marechal-de-Lattre-de-Tassigny, BP 77908, 21000 Dijon, France.;Centre regional de pharmacovigilance, service de pharmacologie clinique, hopital;Bretonneau, 2, boulevard Tonnelle, 37044 Tours cedex 9, France.;Electronic address: thierry.vial@chu-lyon.fr. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/24953526/ |
|---|
